- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CMS Eliminates Outdated Rules, Projects Provider Savings of $660M a Year
Final rule reduces burdens to critical access hospitals, rural clinics; loosens physician supervision requirements.
Hospitals will save approximately $660 million a year thanks to a new government rule that removes unnecessary, obsolete or burdensome regulations, according to the Centers for Medicare & Medicaid Services (CMS).
The reforms, announced yesterday in a final rule, eliminates requirements that hinder hospitals or other healthcare organizations from providing high-quality patient care, the agency said in an announcement. CMS estimates organizations will save roughly $3.2 billion over the next five years as a result of the new rule. In addition, it projects that combined with President Barack Obama's "regulatory look-back" executive order, the two rules will save healthcare providers $8 million over the course of five years.
"By eliminating stumbling blocks and red tape we can assure that the healthcare that reaches patients is more timely, that it's the right treatment for the right patient, and greater efficiency improves patient care across the board," said CMS Administrator Marilyn Tavenner in the announcement.
Read the full story here: http://bit.ly/1qmiASE
Source: Fierce Healthcare
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
High Drug Costs, PBM Reform, and Access Challenges Take Center Stage at AMCP 2025
March 25th 2025As managed care pharmacy navigates rapid transformations in policies, high-cost drug strategies, and innovative therapies, the upcoming AMCP annual meeting will provide critical insights into legislative impacts, drug affordability, formulary design, and emerging treatment trends.
Read More
